The preliminary study by Chai et al. suggested that ACE-2 receptor expression is enriched in cholangiocytes, indicating that COVID-19 might directly bind to ACE-2-positive cholangiocytes to dysregulate liver function (15). The gene discussed is ACE2; the disease is COVID-19.